• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Clinical analysis of 78 pulmonary sarcomatoid carcinomas with surgical treatment.78 例肺肉瘤样癌患者外科治疗的临床分析。
J Int Med Res. 2022 Oct;50(10):3000605221128092. doi: 10.1177/03000605221128092.
2
[Postoperative survival analysis of patients with stage Ⅲ-pN2 non-small cell lung cancer].Ⅲ期-pN2非小细胞肺癌患者的术后生存分析
Zhonghua Zhong Liu Za Zhi. 2018 Oct 23;40(10):782-786. doi: 10.3760/cma.j.issn.0253-3766.2018.10.011.
3
Lymph-node ratio predicts survival among the different stages of non-small-cell lung cancer: a multicentre analysis†.淋巴结比率可预测非小细胞肺癌不同分期的生存情况:一项多中心分析†。
Eur J Cardiothorac Surg. 2019 Mar 1;55(3):405-412. doi: 10.1093/ejcts/ezy311.
4
Prognostic score for survival with pulmonary carcinoids: the importance of associating clinical with pathological characteristics.肺类癌生存的预后评分:临床与病理特征联合的重要性。
Interact Cardiovasc Thorac Surg. 2020 Sep 1;31(3):315-323. doi: 10.1093/icvts/ivaa114.
5
Pathologic Findings and Long-Term Results After Surgical Treatment for Pulmonary Sarcomatoid Tumors: A Multicenter Analysis.肺肉瘤样肿瘤手术治疗后的病理结果及长期疗效:一项多中心分析
Ann Thorac Surg. 2017 Apr;103(4):1142-1150. doi: 10.1016/j.athoracsur.2016.08.114. Epub 2016 Dec 24.
6
Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer.腋窝淋巴结转移阳性率可预测非转移性乳腺癌患者的生存率。
Acta Oncol. 2008;47(2):232-8. doi: 10.1080/02841860701678761.
7
[Value of metastatic lymph node ratio in predicting the prognosis of non-small cell lung cancer patients].[转移淋巴结比率在预测非小细胞肺癌患者预后中的价值]
Zhonghua Yi Xue Za Zhi. 2011 Jun 28;91(24):1682-6.
8
Lymph node involvement and metastatic lymph node ratio influence the survival of malignant pleural mesothelioma: a French multicenter retrospective study.淋巴结受累和转移淋巴结比率影响恶性胸膜间皮瘤的生存:一项法国多中心回顾性研究。
Oncol Rep. 2014 Jan;31(1):415-21. doi: 10.3892/or.2013.2800. Epub 2013 Oct 18.
9
Establishment of a Competing Risk Nomogram in Patients with Pulmonary Sarcomatoid Carcinoma.建立肺肉瘤样癌患者的竞争风险列线图。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338211068960. doi: 10.1177/15330338211068960.
10
The role of prognostic nutritional index in the management of pulmonary sarcomatoid carcinoma.预后营养指数在肺肉瘤样癌管理中的作用。
Clin Sarcoma Res. 2020 Dec 7;10(1):26. doi: 10.1186/s13569-020-00148-2.

引用本文的文献

1
Effect of histological subtype on the efficacy of perioperative chemotherapy in pulmonary sarcomatoid carcinoma: a retrospective study based on SEER population.组织学亚型对肺肉瘤样癌围手术期化疗疗效的影响:一项基于监测、流行病学与结果(SEER)数据库人群的回顾性研究
Transl Lung Cancer Res. 2024 Apr 29;13(4):749-762. doi: 10.21037/tlcr-24-41. Epub 2024 Apr 17.
2
Biological characteristics and clinical treatment of pulmonary sarcomatoid carcinoma: a narrative review.肺肉瘤样癌的生物学特性及临床治疗:一项叙述性综述
Transl Lung Cancer Res. 2024 Mar 29;13(3):635-653. doi: 10.21037/tlcr-24-127. Epub 2024 Mar 27.
3
[A Case of Multidomain Integrated Treatment Strategy 
for Complex Primary Pulmonary Sarcomatoid Carcinoma].[复杂原发性肺肉瘤样癌的多领域综合治疗策略病例]
Zhongguo Fei Ai Za Zhi. 2024 Feb 20;27(2):157-160. doi: 10.3779/j.issn.1009-3419.2024.102.04.
4
Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review.帕博利珠单抗联合安罗替尼提高 TMB-H 和 PD-L1 表达的肺肉瘤样癌的疗效:病例报告及文献复习。
Front Immunol. 2023 Oct 23;14:1274937. doi: 10.3389/fimmu.2023.1274937. eCollection 2023.

本文引用的文献

1
Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma.综合分子特征分析揭示了肺肉瘤样癌的潜在治疗策略。
Nat Commun. 2020 Sep 28;11(1):4878. doi: 10.1038/s41467-020-18702-3.
2
Pulmonary sarcomatoid carcinoma: progress, treatment and expectations.肺肉瘤样癌:进展、治疗与展望。
Ther Adv Med Oncol. 2020 Aug 25;12:1758835920950207. doi: 10.1177/1758835920950207. eCollection 2020.
3
Dramatic Response of Pulmonary Sarcomatoid Carcinoma to Nivolumab Combined with Anlotinib: A Case Report.肺肉瘤样癌对纳武利尤单抗联合安罗替尼的显著反应:一例报告
Case Rep Oncol. 2020 Jun 4;13(2):601-605. doi: 10.1159/000507568. eCollection 2020 May-Aug.
4
Tumor Spread Through Air Spaces Is a Predictor of Occult Lymph Node Metastasis in Clinical Stage IA Lung Adenocarcinoma.空气传播肿瘤是临床 IA 期肺腺癌隐匿性淋巴结转移的预测因子。
J Thorac Oncol. 2020 May;15(5):792-802. doi: 10.1016/j.jtho.2020.01.008. Epub 2020 Jan 30.
5
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.度伐利尤单抗化疗和放疗后用于 III 期非小细胞肺癌的总生存。
N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.
6
Lobectomy Is Associated with Better Outcomes than Sublobar Resection in Spread through Air Spaces (STAS)-Positive T1 Lung Adenocarcinoma: A Propensity Score-Matched Analysis.肺段切除术与亚肺叶切除术治疗空气传播途径阳性 T1 期肺腺癌的疗效比较:一项倾向评分匹配分析。
J Thorac Oncol. 2019 Jan;14(1):87-98. doi: 10.1016/j.jtho.2018.09.005. Epub 2018 Sep 19.
7
Pulmonary Sarcomatoid Carcinomas: A Review.肺肉瘤样癌:综述。
Adv Anat Pathol. 2018 Sep;25(5):304-313. doi: 10.1097/PAP.0000000000000202.
8
Sarcomatoid Carcinoma of the Lung: The Mayo Clinic Experience in 127 Patients.肺肉瘤样癌:梅奥诊所 127 例患者的经验。
Clin Lung Cancer. 2018 May;19(3):e323-e333. doi: 10.1016/j.cllc.2017.12.008. Epub 2017 Dec 21.
9
Pulmonary sarcomatoid carcinoma: University of Cincinnati experience.肺肉瘤样癌:辛辛那提大学的经验
Oncotarget. 2017 Dec 18;9(3):4102-4108. doi: 10.18632/oncotarget.23468. eCollection 2018 Jan 9.
10
Spread through air spaces (STAS): a comprehensive update.通过气腔播散(STAS):全面更新
Transl Lung Cancer Res. 2017 Oct;6(5):501-507. doi: 10.21037/tlcr.2017.06.08.

78 例肺肉瘤样癌患者外科治疗的临床分析。

Clinical analysis of 78 pulmonary sarcomatoid carcinomas with surgical treatment.

机构信息

Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin, China.

Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.

出版信息

J Int Med Res. 2022 Oct;50(10):3000605221128092. doi: 10.1177/03000605221128092.

DOI:10.1177/03000605221128092
PMID:36224744
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9561649/
Abstract

OBJECTIVE

To evaluate clinical factors influencing the postoperative pulmonary sarcomatoid carcinoma (PSCs) prognosis.

METHODS

We retrospectively evaluated patients with PSCs treated from October 2012 to October 2017. Kaplan-Meier survival curves were calculated using univariable analysis (log-rank test). Univariable/multivariable Cox regression analysis was also performed.

RESULTS

Mixed PSCs were most common (64.10%). Pure PSCs occurred more often with large tumors compared with mixed PSCs. Patients with vs without pleural retraction, respectively, had significantly worse overall survival (OS; 16 vs 23 months) and disease-free survival (DFS; 11 vs 20 months), and patients with airway dissemination had significantly shorter OS (14 vs 21 months) and DFS (11 vs 20 months). Patients with PSC with an adenocarcinoma component had favorable OS. Airway dissemination, pleural retraction, metastatic mediastinal lymph node (LN) number, and pathological tumor-node-metastasis (pTNM) stage were risk factors for short OS. Neither adjuvant chemotherapy nor adjuvant radiotherapy provided a survival advantage. Airway dissemination was an independent prognostic factor (odds ratio, 1.87; 95% confidence interval, 1.04-3.36).

CONCLUSION

Pure PSCs were more likely with large tumors compared with mixed PSCs. Airway dissemination, pleural retraction, and metastatic mediastinal LN number were associated with OS. Airway dissemination was an independent prognostic factor.

摘要

目的

评估影响肺肉瘤样癌(PSCs)术后预后的临床因素。

方法

我们回顾性评估了 2012 年 10 月至 2017 年 10 月期间接受治疗的 PSCs 患者。使用单变量分析(对数秩检验)计算 Kaplan-Meier 生存曲线。还进行了单变量/多变量 Cox 回归分析。

结果

混合 PSCs 最常见(64.10%)。与混合 PSCs 相比,纯 PSCs 更常发生于大肿瘤患者。与无胸膜回缩的患者相比,有胸膜回缩的患者总生存期(OS;16 个月 vs 23 个月)和无病生存期(DFS;11 个月 vs 20 个月)明显更差,气道播散的患者 OS(14 个月 vs 21 个月)和 DFS(11 个月 vs 20 个月)明显更短。具有腺癌成分的 PSC 患者 OS 良好。气道播散、胸膜回缩、转移性纵隔淋巴结(LN)数量和病理肿瘤-淋巴结-转移(pTNM)分期是 OS 较短的危险因素。辅助化疗和辅助放疗均不能带来生存优势。气道播散是独立的预后因素(优势比,1.87;95%置信区间,1.04-3.36)。

结论

与混合 PSCs 相比,纯 PSCs 更可能发生于大肿瘤患者。气道播散、胸膜回缩和转移性纵隔 LN 数量与 OS 相关。气道播散是独立的预后因素。